Mineralys Therapeutics (MLYS) Share-based Compensation (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Share-based Compensation data on file, last reported at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 79.64% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $22.2 million (up 73.78% YoY), and the FY2025 full-year result was $19.3 million, up 70.47% from the prior year.
• Share-based Compensation grew to $6.5 million in Q1 2026, from $5.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.5 million in Q1 2026 to a low of $19000.0 in Q1 2022.
• A 5-year average of $2.5 million and a median of $2.2 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 4807.69% in 2023 and soared 58.53% in 2025, its largest moves.
• Tracing MLYS's Share-based Compensation over 5 years: stood at $218000.0 in 2022, then soared by 568.35% to $1.5 million in 2023, then jumped by 115.1% to $3.1 million in 2024, then soared by 68.63% to $5.3 million in 2025, then gained by 23.9% to $6.5 million in 2026.
• Business Quant data shows MLYS's Share-based Compensation at $6.5 million in Q1 2026, $5.3 million in Q4 2025, and $5.8 million in Q3 2025.